Sleep Cycle（SLEEP）株式概要
Sleep Cycle AB (publish)は、スウェーデンで睡眠追跡アプリケーションを提供している。 詳細
SLEEP Community Fair Values
Create NarrativeSee what 67 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Software opportunity
JO
Fair Value from
US$6.8565.1% 割安 内在価値ディスカウント
ZenaTech: A big bet on the rise of AI drones and drones-as-a-service
Key Takeaways ZenaTech is focusing its efforts into building AI drones, combining Drone as a Service, SaaS, and AI as its key revenue drivers. Previously building software for agriculture, ZenaTech has shifted rapidly toward drone services, now driving ~70% of revenue after recent acquisitions.
Read full narrativeSleep Cycle AB (publ) 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | SEK 15.34 |
| 52週高値 | SEK 34.70 |
| 52週安値 | SEK 14.84 |
| ベータ | 0.013 |
| 1ヶ月の変化 | -12.34% |
| 3ヶ月変化 | -36.08% |
| 1年変化 | -50.52% |
| 3年間の変化 | -65.06% |
| 5年間の変化 | n/a |
| IPOからの変化 | -80.78% |
最新ニュース
Recent updates
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00
May 02
SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery
Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).
SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential
Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside
Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside
Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside
Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts
Feb 09Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53
Feb 07
SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play
Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside
Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside
Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings
Jan 04SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential
Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%
Sep 09Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.
Aug 27
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities
Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
Apr 30The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%
Apr 29Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
Apr 08
Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships
Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's
Mar 06Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year
Feb 10Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model
Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device for株主還元
| SLEEP | SE Software | SE 市場 | |
|---|---|---|---|
| 7D | -17.9% | 0.7% | -1.9% |
| 1Y | -50.5% | -41.7% | 11.0% |
業界別リターン: SLEEP過去 1 年間で-41.7 % の収益を上げたSwedish Software業界を下回りました。
リターン対市場: SLEEPは、過去 1 年間で11 % のリターンを上げたSwedish市場を下回りました。
価格変動
| SLEEP volatility | |
|---|---|
| SLEEP Average Weekly Movement | 7.7% |
| Software Industry Average Movement | 9.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.8% |
安定した株価: SLEEP 、 Swedish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: SLEEPの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2001 | 39 | Erik Jivmark | sleepcycle.com |
Sleep Cycle AB (publish)はスウェーデンで睡眠追跡アプリケーションの提供に従事している。睡眠と健康のプラットフォームを開発。同社は睡眠関連ソリューションを提供するアプリケーション、Sleep Cycle appを提供している。Sleep Cycle AB (publ)は2001年に設立され、スウェーデンのヨーテボリを拠点としている。
Sleep Cycle AB (publ) 基礎のまとめ
| SLEEP 基礎統計学 | |
|---|---|
| 時価総額 | SEK 311.06m |
| 収益（TTM） | SEK 44.92m |
| 売上高(TTM) | SEK 235.96m |
6.9x
PER（株価収益率1.3x
P/SレシオSLEEP は割高か？
公正価値と評価分析を参照収益と収入
| SLEEP 損益計算書（TTM） | |
|---|---|
| 収益 | SEK 235.96m |
| 売上原価 | SEK 100.65m |
| 売上総利益 | SEK 135.31m |
| その他の費用 | SEK 90.39m |
| 収益 | SEK 44.92m |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 26, 2026
| 一株当たり利益（EPS） | 2.22 |
| グロス・マージン | 57.34% |
| 純利益率 | 19.04% |
| 有利子負債／自己資本比率 | 0% |
SLEEP の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
3.5%
現在の配当利回り24%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/04 23:11 |
| 終値 | 2026/05/04 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Sleep Cycle AB (publ) 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Oscar Erixon | Carnegie Investment Bank AB |
| Erik Granström | DNB Carnegie |
| Rikard Engberg | DNB Carnegie Commissioned Research |